33 related articles for article (PubMed ID: 6668481)
1. Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy.
Ghiami H; Omidkhoda N; Seddigh-Shamsi M; Rahimi H; Arasteh O
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3771-3780. PubMed ID: 38095650
[TBL] [Abstract][Full Text] [Related]
2. Assessing anthracycline cardiotoxicity in the 1990s.
Carrió I; Estorch M; López-Pousa A
Eur J Nucl Med; 1996 Apr; 23(4):359-64. PubMed ID: 8612653
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of anticancer drugs in children.
Crom WR; Glynn-Barnhart AM; Rodman JH; Teresi ME; Kavanagh RE; Christensen ML; Relling MV; Evans WE
Clin Pharmacokinet; 1987 Mar; 12(3):168-213. PubMed ID: 3555940
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.
Bouma J; Beijnen JH; Bult A; Underberg WJ
Pharm Weekbl Sci; 1986 Apr; 8(2):109-33. PubMed ID: 3520474
[TBL] [Abstract][Full Text] [Related]
5. Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.
Mormont MC; von Roemeling R; Sothern RB; Berestka JS; Langevin TR; Wick M; Hrushesky WJ
Invest New Drugs; 1988 Dec; 6(4):273-83. PubMed ID: 3229940
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of doxorubicin in man: dose and schedule dependence.
Erttmann R; Erb N; Steinhoff A; Landbeck G
J Cancer Res Clin Oncol; 1988; 114(5):509-13. PubMed ID: 3182911
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.
Greidanus J; Willemse PH; Uges DR; Oremus ET; De Langen ZJ; De Vries EG
Pharm Weekbl Sci; 1988 Dec; 10(6):237-45. PubMed ID: 3062572
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Hiddemann W; Büchner T
Blut; 1990 Mar; 60(3):163-71. PubMed ID: 2180498
[TBL] [Abstract][Full Text] [Related]
9. Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Hrubisko M; Mc Gown AT; Prendiville JA; Radford JA; Thatcher N; Fox BW
Cancer Chemother Pharmacol; 1992; 29(3):252-5. PubMed ID: 1733559
[TBL] [Abstract][Full Text] [Related]
10. Clinical toxicity associated with tiazofurin.
Grem JL; Rubinstein L; King SA; Cheson BD; Hawkins MJ; Shoemaker DD
Invest New Drugs; 1990 May; 8(2):227-38. PubMed ID: 2200759
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity.
Lum BL; Svec JM; Torti FM
Drug Intell Clin Pharm; 1985 Apr; 19(4):259-64. PubMed ID: 3891276
[TBL] [Abstract][Full Text] [Related]
12. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system.
Lokich J; Bothe A; Zipoli T; Green R; Sonneborn H; Paul S; Philips D
J Clin Oncol; 1983 Jan; 1(1):24-8. PubMed ID: 6668481
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemotherapy via ambulatory infusion pump.
Lokich JJ; Perri J; Bothe A; Zipoli T; Philips D; Sonneborn H; Paul S; Green R
Am J Clin Oncol; 1983 Jun; 6(3):355-63. PubMed ID: 6405610
[TBL] [Abstract][Full Text] [Related]
14. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of combining metronidazole with chemotherapy.
Stewart DJ; Maroun JA; Young V; Crook AF; Hopkins HS; Yan RC; Richard MT; Hugenholtz H; Bélanger R; Heringer R
J Clin Oncol; 1983 Jan; 1(1):17-23. PubMed ID: 6422002
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
